Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc.

      Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG
                            Pharmaceuticals, Inc.

PR Newswire

NEW YORK, Sept. 25, 2013

NEW YORK, Sept. 25, 2013 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC is
investigating potential claims on behalf of purchasers of the securities of
AMAG Pharmaceuticals, Inc. ("AMAG Pharmaceuticals" or the "Company")
(NasdaqGS: AMAG). The investigation focuses on whether the Company and its
executives complied with federal securities laws.

On September 25, 2013, shares of AMAG Pharmaceuticals fell $3.53 or 13.49%
during intraday trading to trade at $22.63 after the company disclosed in a
regulatory filing that it had received a notification from the FDA in
connection with the Company's supplemental New Drug Application for its
Feraheme Injection on September 23, 2013. The FDA stated, "that, as part of
its ongoing review of the Company's sNDA, the FDA has identified deficiencies
that preclude discussion of labeling and postmarketing
requirements/commitments by September 23, 2013, a target date previously
communicated by the FDA in a letter dated March 5, 2013."

If you are aware of any facts relating to this investigation, or purchased
shares of AMAG Pharmaceuticals, you can assist this investigation by
contacting Peretz Bronstein or his Investor Relations Coordinator Eitan
Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email
info@bgandg.com. Those who inquire by e-mail are encouraged to include their
mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our
primary expertise is the aggressive pursuit of litigation claims on behalf of
our clients. In addition to representing institutions and other investor
plaintiffs in class action security litigation, the firm's expertise includes
general corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not guarantee similar
outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein 212-697-6484
info@bgandg.com



SOURCE Bronstein, Gewirtz & Grossman, LLC

Website: http://www.bgandg.com
 
Press spacebar to pause and continue. Press esc to stop.